FDA Blocks Seikagaku's US Bid for Back-Pain Drug Over Factory Deficiencies, Not the Data
Seikagaku's Complete Response Letter from the FDA flags unresolved deficiencies at its active-ingredient plant and new problems at a contract formulator for SI-6603, with no concerns raised about the drug's efficacy or safety data and no resubmission date given.